nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

13. Autismus-Spektrum-Störungen

verfasst von : Prof. Dr. med. Christine M. Freitag, Dr. Tomasz A. Jarczok

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Psychopharmakologische Ansätze bei Autismus-Spektrum-Störungen sind aktuell vor allem darauf gerichtet, bestimmte, teilweise auch nur komorbide auftretende Verhaltensweisen oder zusätzliche psychische Störungen zu verbessern. Es gibt einzelne Versuche, die zentrale autistische Symptomatik im Bereich der sozialen Interaktion, Kommunikation, Sprache und vor allem auch im Bereich des stereotypen Verhaltens zu verbessern. Dies ist aktuell nur bezüglich des stereotypen Verhaltens erfolgreich gelungen. In dem folgenden Kapitel sind deshalb differenziell Neuro‑/Psychopharmaka aufgeführt, die bestimmte Zielsymptome bei Autismus-Spektrum-Störungen verbessern. Dabei wurde überwiegend auf Psychopharmaka rekurriert, die einen Evidenzgrad von 2 und besser aufweisen.

Aman MG, Arnold LE, McDougle CJ et al. (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15:869–884PubMedCrossRef

Aman MG, McDougle CJ, Scahill L et al. (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48:1143–1154PubMedCrossRef

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5. Aufl. American Psychiatric PublishingCrossRef

Anderson LT, Campbell M, Grega DM et al. (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195–1202PubMedCrossRef

Baribeau D, Vorstman J, Anagnostou E (2022) Novel treatments in autism spectrum disorder. Br J Psychiatry 35:101–110. https://doi.org/10.1097/YCO.0000000000000775CrossRef

Baxter AJ, Brugha TS, Erskine HE et al. (2015) The epidemiology and global burden of autism spectrum disorders. Psychol Med 45:601–613PubMedCrossRef

Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW (2001) Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31:175–181PubMedCrossRef

Celik G, Tahiroglu AY, Firat S, Avci A (2011) Aripiprazole improved obsessive compulsive symptoms in Asperger’s disorder. Clin Psychopharmacol Neurosci 9:134–136PubMedPubMedCentralCrossRef

Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ (2004) A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531–1536PubMedCrossRef

Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D (2012) Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 21:700–709PubMedCrossRef

Cuomo BM, Vaz S, Lee EAL et al. (2017) Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis. Pharmacotherapy 37:555–578PubMedCrossRef

D’Alò GL, de Crescenzo F, Amato L et al. (2021) Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health Qual Life Outcomes 19:33PubMedPubMedCentralCrossRef

Doyle CA, McDougle CJ (2012) Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 14:263–279PubMedPubMedCentralCrossRef

Dubreucq J, Haesebaert F, Plasse J, Dubreucq M, Franck N (2022) A systematic review and meta-analysis of social skills training for adults with autism spectrum disorder. J Autism Dev Disord 52:1598–1609PubMedCrossRef

Elnaiem W, Benmelouka AY, Elgendy AMN et al. (2022) Evaluation of memantine’s efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. Hum Psychopharmacol Clin Exp 37:e2841. https://doi.org/10.1002/hup.2841CrossRef

Fallah MS, Shaikh MR, Neupane B et al. (2019) Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol 29:168–180PubMedCrossRef

Freitag CM (2021) Von den tiefgreifenden Entwicklungsstörungen in ICD-10 zur Autismus-Spektrum-Störung in ICD-11. Z Kinder Jugendpsychiatrie Psychother 49:437–441CrossRef

Freitag CM, Jensen K, Elsuni L et al. (2016) Group-based cognitive behavioural psychotherapy for children and adolescents with ASD: the randomized, multicentre, controlled SOSTA-net trial. J Child Psych Psychiatry 57:596–605CrossRef

Freitag CM, Chiocchetti AG, Haslinger D, Yousaf A, Waltes R (2022) Genetic risk factors and their influence on neural development in autism spectrum disorders. Z Kinder Jugendpschiatrie Psychother 50:187–202. https://doi.org/10.1024/1422-4917/a000803CrossRef

Fung LK, Mahajan R, Nozzolillo A et al. (2016) Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics 137:[Suppl 2]:S124–35PubMedCrossRef

Gates JA, Kang E, Lerner MD (2017) Efficacy of group social skills interventions for youth with autism spectrum disorder: a systematic review and meta-analysis. Clin Psychol Rev 52:164–181PubMedPubMedCentralCrossRef

Golubchik P, Sever J, Weizman A (2013) Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial. Clin Neuropharm 36:37–41CrossRef

Hardan AY, Jou RJ, Handen BL (2005) Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35:387–391PubMedCrossRef

Hirota T, Veenstra-VanderWeele J, Hollander E, Kishi T (2014) Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. J Autism Dev Disord 44:948–957PubMedCrossRef

Hirsch LE, Pringsheim T (2016) Aripiprazole for autism spectrum disorders (ASD). Chochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009043.pub3CrossRef

Hollander E, Wasserman S, Swanson EN et al. (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16:541–548PubMedCrossRef

Hurwitz R, Blackmore R, Hazell P, Williams K, Woolfenden S (2012) Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008372.pub2CrossRefPubMed

Ibrahim SH, Voigt RG, Katusic SK, Weaver AL, Barbaresi WJ (2009) Incidence of gastrointestinal symptoms in children with autism: a population-based study. Pediatrics 124:680–686PubMedCrossRef

Kim Y, Cho S-C, Shin M-S, et al. (2010) Retrospective case series of aripiprazole augmentation in pervasive developmental disorders. Psychiatry Investig 7:220–223PubMedPubMedCentralCrossRef

King BH, Hollander E, Sikich L et al. (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66:583–590PubMedPubMedCentralCrossRef

Krakowiak P, Goodlin-Jones B, Hertz-Picciotto I, Croen LA, Hansen RL (2008) Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-based study. J Sleep Res 17:197–206PubMedPubMedCentralCrossRef

Krishnaswami S, McPheeters ML, Veenstra-VanderWeele J (2011) A systematic review of secretin for children with autism spectrum disorders. Pediatrics 127:E1322–E1325PubMedPubMedCentralCrossRef

Lai MC, Kassee C, Besney R et al. (2019) Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry 6:819–829PubMedCrossRef

Lee T-M, Lee K-M, Lee C-Y et al. (2021) Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials. Aust N Z J Psychiatry 55:196–206PubMedCrossRef

Leyfer OT, Folstein SE, Bacalman S et al. (2006) Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 36:849–861PubMedCrossRef

Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17:779–790PubMedCrossRef

McCracken JT, McGough J, Shah B et al. (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321PubMedCrossRef

Pan P-Y, Bölte S, Kaur P, Jamil S, Jonsson U (2021) Neurological disorders in autism: a systematic review and meta-analysis. Autism 25:812–883PubMedCrossRef

Perihan C, Burke M, Bowman-Perrott L et al. (2020) Effects of cognitive behavioral therapy for reducing anxiety in children with high functioning ASD: a systematic review and meta-analysis. J Autism Dev Disord 50:1958–1972PubMedCrossRef

Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ (2001) A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 11:267–277PubMedCrossRef

Rodrigues R, Lai M-C, Beswick A et al. (2021) Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. J Child Psychol Psychiatry 62:680–700PubMedCrossRef

Sandbank M, Bottema-Beutel K, Crowley S et al. (2020) Project AIM: Autism intervention meta-analysis for studies of young children. Psychol Bull 146:1–29PubMedCrossRef

Sharma S, Hucker A, Matthews T, Grohmann D, Laws KR (2021) Cognitive behavioural therapy for anxiety in children and young people on the autism spectrum: a systematic review and meta-analysis. BMC Psychol 9:151PubMedPubMedCentralCrossRef

Siafis S, Çıray O, Wu H et al. (2022) Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism 13:10PubMedPubMedCentralCrossRef

Siegel M (2012) Psychopharmacology of autism spectrum disorder. Child Adolesc Psychiatric Clin N Am 21:957–973CrossRef

Simonoff E, Pickles A, Charman T et al. (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Amercian Acad Child Adolesc Psychiatry 47:921–929CrossRef

Tarver J, Palmer M, Webb S et al. (2019) Child and parent outcomes following parent interventions for child emotional and behavioral problems in autism spectrum disorders: a systematic review and meta-analysis. Autism 23:1630–1644PubMedCrossRef

Thorkelson G, Laughlin SF, Turner KS, Ober N, Handen BL (2019) Selective serotonin Reuptake inhibitor monotherapy for anxiety disorders in children and adolescents with autism spectrum disorder: a chart review. J Child Adolesc Psychopharmacol 29:705–711PubMedCrossRef

Wasserman S, Iyengar R, Chaplin WF et al. (2006) Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 21:363–367PubMedCrossRef

Williams K, Brignell A, Randall M, Silove N, Hazell P (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Chochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004677.pub2CrossRef

Zimmer MH, Hart LC, Manning-Court MDS, Bing NM, Summer S (2012) Food variety as a predictor of nutritional status among children with autism. J Autism Dev Disord 42:549–556PubMedPubMedCentralCrossRef

Titel: Autismus-Spektrum-Störungen
verfasst von: Prof. Dr. med. Christine M. Freitag
Dr. Tomasz A. Jarczok
Verlag: Springer Berlin Heidelberg
Buch: Neuro-/Psychopharmaka im Kindes- und Jugendalter
Print ISBN: 978-3-662-65266-4

Electronic ISBN: 978-3-662-65267-1

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-65267-1_13

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).